Generic Name: bortezomib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Takeda

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Velcade is a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma.

General Info

Velcade is a proteasome inhibitor that targets an enzyme that digests and eliminates excess proteins in myeloma cells. Blocking proteasome activity leads to myeloma cell death.

Clinical trials showed that Velcade slows progression of multiple myeloma and improves survival.


Dosing Info:

Velcade is administered as either a subcutaneous injection or an intravenous infusion, given twice weekly for four six-week cycles then once weekly.

Side Effects

Common side effects include nausea, diarrhea, peripheral neuropathy and nerve pain, fatigue, constipation, skin rash, fever and decreased appetite. It can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. It can cause birth defects and should not be used during pregnancy.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 18, 2018